title: Apolipoprotein A-I mimetic peptides.
abstract: Despite identical amino acid composition, differences in class A amphipathic helical peptides caused by differences in the order of amino acids on the hydrophobic face results in substantial differences in antiinflammatory properties. One of these peptides is an apolipoprotein A-I (apoA-I) mimetic, D-4F. When given orally to mice and monkeys, D-4F caused the formation of pre-beta high-density lipoprotein (HDL), improved HDL-mediated cholesterol efflux, reduced lipoprotein lipid hydroperoxides, increased paraoxonase activity, and converted HDL from pro-inflammatory to antiinflammatory. In apolipoprotein E (apoE)-null mice, D-4F increased reverse cholesterol transport from macrophages. Oral D-4F reduced atherosclerosis in apoE-null and low-density lipoprotein (LDL) receptor-null mice. In vitro when added to human plasma at nanomolar concentrations, D-4F caused the formation of pre-beta HDL, reduced lipoprotein lipid hydroperoxides, increased paraoxonase activity, and converted HDL from pro-inflammatory to antiinflammatory. Physical-chemical properties and the ability of various class A amphipathic helical peptides to activate lecithin cholesterol acyltransferase (LCAT) in vitro did not predict biologic activity in vivo. In contrast, the use of cultured human artery wall cells in evaluating these peptides was more predictive of their efficacy in vivo. We conclude that the antiinflammatory properties of different class A amphipathic helical peptides depends on subtle differences in the configuration of the hydrophobic face of the peptides, which determines the ability of the peptides to sequester inflammatory lipids. These differences appear to be too subtle to predict efficacy based on physical-chemical properties alone. However, understanding these physical-chemical properties provides an explanation for the mechanism of action of the active peptides.
authors.affiliation: Division of Cardiology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, Calif 90095-1679, USA. mnavab@mednet.ucla.edu
authors.forename: Mohamad
authors.initials: M
authors.lastname: Navab
authors.forename: G M
authors.initials: GM
authors.lastname: Anantharamaiah
authors.forename: Srinivasa T
authors.initials: ST
authors.lastname: Reddy
authors.forename: Susan
authors.initials: S
authors.lastname: Hama
authors.forename: Greg
authors.initials: G
authors.lastname: Hough
authors.forename: Victor R
authors.initials: VR
authors.lastname: Grijalva
authors.forename: Nicholas
authors.initials: N
authors.lastname: Yu
authors.forename: Benjamin J
authors.initials: BJ
authors.lastname: Ansell
authors.forename: Geeta
authors.initials: G
authors.lastname: Datta
authors.forename: David W
authors.initials: DW
authors.lastname: Garber
authors.forename: Alan M
authors.initials: AM
authors.lastname: Fogelman
mesh_terms: D000818:Animals; D016632:Apolipoprotein A-I / Q000737:chemistry* / Q000378:metabolism*; D006801:Humans; D018716:Molecular Mimicry; D010455:Peptides / Q000737:chemistry* / Q000378:metabolism*; D017433:Protein Structure, Secondary
chemical_list: D016632:Apolipoprotein A-I; D010455:Peptides